OUR STRATEGIC FRAMEWORK

• Convene the multi-stakeholder community around the ACCELERATE Annual Conference, with meetings taking place on 5–6 February 2026 and 4–5 February 2027, creating a neutral forum where clinicians, researchers, regulators, industry representatives, patient advocates and other partners can exchange perspectives, identify priorities and shape future action.
• Support the implementation of ACCELERATE initiatives in additional regions, including the development of stronger international links that broaden the platform’s reach and relevance.
• Expand participation across academia, industry, advocacy, charities and international partners, with a particular focus on strengthening engagement from biotechnology companies and philanthropic stakeholders.
• Further develop a connected charity and advocacy network that helps ensure the voices of children, adolescents, families and supporters remain visible in discussions on paediatric oncology drug development.

Paediatric Strategy and Impact Forums

• B7-H3 Paediatric Strategy Forum, Paris, 29–30 October 2026: this forum will bring together the multi-stakeholder community to assess the scientific and clinical rationale for targeting B7-H3 in paediatric and adolescent malignancies, review the range of assets in development, identify areas of unmet need, and support prioritisation of the most promising approaches for children and adolescents with cancer.
• BCL2 Impact Forum, Amsterdam, 14 October 2026: this meeting will examine opportunities and challenges in the development of BCL2-targeting medicines for paediatric cancers, with the aim of aligning stakeholders on where these approaches may offer the greatest value and how development pathways can be advanced efficiently.
• Ewing Sarcoma Paediatric Strategy Forum, planned for Q3 2027: this forum being organised in partnership with the Ewing Sarcoma Institute will focus on development priorities for Ewing sarcoma, helping stakeholders review the emerging landscape, define key unmet needs, and identify practical routes to accelerate access to promising therapeutic options.

Working groups

• Fair Trials: Advance ongoing work on age-inclusive research to support drug development strategies that better reflect the needs of adolescents and young adults within paediatric oncology.
• PROs: Continue work on patient-reported outcomes to strengthen the integration of the patient perspective into research, trial design and evaluation of treatment benefit.
• Develop work on reviving deprioritised assets, exploring how compounds that may no longer be strategic for adult development could still hold value for children and adolescents with cancer.

Workshops resulting in Working Groups and ongoing initiatives

• Deprioritised assets workshop, New York, 5 March 2026. The group agreed to develop and pilot a turnkey approach for pharmaceutical and biotech companies and teams plus a clear intake/evaluation pathway to move deprioritized assets out of industry efficiently.
• Logbook workshop, Milan, 3 June 2026 will review ongoing programs collecting survivorship data in several countries and support collaborative planning on long-term follow-up strategies of innovative new drugs and data generation.
• Child First workshop, London, 28 & 29 September will explore how paediatric needs can be addressed earlier and more effectively in the development pathway for innovative medicines.

Topic development, research and ongoing initiatives

• In collaboration with IQVIA, develop a comprehensive, data-driven view of global trends in paediatric oncology research, clinical development, regulatory activity, and access to innovation.
• Prepare new strategic topics through online meetings and targeted exchanges, including educational follow-up linked to previous initiatives and emerging scientific priorities.
• Advance research projects that help document outcomes from Paediatric Strategy Forums and contribute to a stronger evidence base for future prioritisation and policy discussions.
• Support ongoing efforts to facilitate implementation of regulatory changes relevant to paediatric oncology drug development.
• Prepare future topics for 2027, including access to academic drugs for academic trials and a potential Impact Forum on drug development in B-cell non-Hodgkin lymphoma.

• Define meaningful metrics to assess the reach, quality and influence of ACCELERATE activities across its community, scientific outputs and strategic initiatives.
• Develop impact reporting that captures how ACCELERATE contributes to collaboration, prioritisation and progress in paediatric oncology drug development.
• Implement a structured stakeholder engagement approach to strengthen participation and ensure that engagement activities are aligned with ACCELERATE’s strategic goals.
• Support publications arising from ACCELERATE activities and projects, helping translate multi-stakeholder strategic dialogue into accessible evidence and recommendations.
• Publication on antibody-drug conjugates and related Strategy Forum discussions.
• Publication on outcomes and follow-up from all assets discussed in the 16 Paediatric Strategy Forums to date.
• Publication on long-term toxicity of new medicinal products following the Logbook workshop
• Publication on the broader impact of ACCELERATE.
• Publication from ALADDIN project Fellow highlighting the challenges of conducting/ authorising paediatric clinical trials in Europe.